Details of the Drug Combination

General Information of Drug Combination (ID: DCQYS9G)

Drug Combination Name

Deferasirox Deferoxamine

Indication

Disease Entry	Status	REF
Sickle Cell Disease	Phase 1	[1]

Component Drugs

Deferasirox DM6ETS0

Deferoxamine DMG0C81

N.A.

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Deferasirox

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Approved	[2]
Iron overload disease	5C64.10	Approved	[2]
Iron metabolism disease	N.A.	Investigative	[2]

Deferasirox Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[6]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Deferasirox Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
DNA-directed RNA polymerase II subunit RPB1 (POLR2A)	OTHJQ1DZ	RPB1_HUMAN	Decreases Phosphorylation	[7]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Activity	[7]
------------------------------------------------------------------------------------

Indication(s) of Deferoxamine

Disease Entry	ICD 11	Status	REF
Acute iron or aluminum toxicity	FB83.20	Approved	[3]
Subarachnoid hemorrhage	8B01	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2	[5]

References

1	ClinicalTrials.gov (NCT00110617) Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
2	Deferasirox FDA Label
3	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207384.
4	Deferoxamine FDA Label
5	ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health.
6	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
7	Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology. 2007 Oct 25;367(2):324-33. doi: 10.1016/j.virol.2007.06.011. Epub 2007 Jul 13.